A modified Delphi consensus regarding the clinical utility of triplet therapy in patients with metastatic hormone-sensitive prostate cancer patients in the UK
Objectives This study aimed to determine the clinical utility of the androgen deprivation therapy (ADT)+docetaxel (DOCE)+androgen receptor-targeted agent (ARTA) triplet therapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the UK.Design A modified Delphi method. A steering...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-11-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/11/e090013.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850062620119269376 |
|---|---|
| author | Louisa Fleure Amit Bahl Suneil Jain Vincent Khoo Noel Clarke Tania Kalsi Hilary Glen Junaid Mobeen |
| author_facet | Louisa Fleure Amit Bahl Suneil Jain Vincent Khoo Noel Clarke Tania Kalsi Hilary Glen Junaid Mobeen |
| author_sort | Louisa Fleure |
| collection | DOAJ |
| description | Objectives This study aimed to determine the clinical utility of the androgen deprivation therapy (ADT)+docetaxel (DOCE)+androgen receptor-targeted agent (ARTA) triplet therapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the UK.Design A modified Delphi method. A steering group of eight UK healthcare professionals experienced in prostate cancer care discussed treatment challenges, developing 39 consensus statements across four topics. Agreement with the statements was tested with a broader panel of professionals within this therapeutic area in the UK through an anonymous survey, using a four-point Likert scale. This was distributed by the steering group members and an independent third party. Following the survey, the steering group convened to discuss the results and formulate recommendations.Setting The steering group convened online for discussions. The survey was distributed via email by the clinicians and the independent third party.Participants Healthcare professionals involved in the provision of prostate cancer care, working in relevant professional roles (oncology, urology or geriatric consultant, oncology nurse specialist, and hospital pharmacist) within the UK. No patients or members of the public were involved within the study.Interventions None.Primary and secondary outcome measures Consensus was defined as high (≥75% agreement) and very high (≥90% agreement).Results Responses were received from 120 healthcare professionals, including oncologists (n=73), urologists (n=16), geriatricians (n=15), nurse specialists (n=11) and hospital pharmacists (n=5). Consensus was reached for 37 out of 39 (95%) statements, and 27/39 (69%) statements achieved very high agreement ≥90%. Consensus was not reached for 2/39 (5%) statements.Conclusions Based on the consensus observed, the steering group developed a set of recommendations for the clinical utility of ADT+DOCE+ARTA in treating patients with mHSPC in the UK. Following these recommendations enables clinicians to identify appropriate patients with mHSPC for triplet treatment, thereby improving patients’ outcomes. |
| format | Article |
| id | doaj-art-282e269aa06b4129aaddbf56e63a55ed |
| institution | DOAJ |
| issn | 2044-6055 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-282e269aa06b4129aaddbf56e63a55ed2025-08-20T02:49:52ZengBMJ Publishing GroupBMJ Open2044-60552024-11-01141110.1136/bmjopen-2024-090013A modified Delphi consensus regarding the clinical utility of triplet therapy in patients with metastatic hormone-sensitive prostate cancer patients in the UKLouisa Fleure0Amit Bahl1Suneil Jain2Vincent Khoo3Noel Clarke4Tania Kalsi5Hilary Glen6Junaid Mobeen73 Guy`s and Saint Thomas` NHS Foundation Trust, London, UK2 University Hospitals Bristol NHS Foundation Trust, Bristol, UK6 Queen`s University Belfast, Belfast, UK8 Department of Oncology, Royal Marsden NHS Foundation Trust, London, UK4 Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK7 Guy`s and St Thomas` NHS Foundation Trust, London, UK1 Beatson West of Scotland Cancer Centre, Glasgow, UK9 Nottingham University Hospitals NHS Trust, Nottingham, UKObjectives This study aimed to determine the clinical utility of the androgen deprivation therapy (ADT)+docetaxel (DOCE)+androgen receptor-targeted agent (ARTA) triplet therapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the UK.Design A modified Delphi method. A steering group of eight UK healthcare professionals experienced in prostate cancer care discussed treatment challenges, developing 39 consensus statements across four topics. Agreement with the statements was tested with a broader panel of professionals within this therapeutic area in the UK through an anonymous survey, using a four-point Likert scale. This was distributed by the steering group members and an independent third party. Following the survey, the steering group convened to discuss the results and formulate recommendations.Setting The steering group convened online for discussions. The survey was distributed via email by the clinicians and the independent third party.Participants Healthcare professionals involved in the provision of prostate cancer care, working in relevant professional roles (oncology, urology or geriatric consultant, oncology nurse specialist, and hospital pharmacist) within the UK. No patients or members of the public were involved within the study.Interventions None.Primary and secondary outcome measures Consensus was defined as high (≥75% agreement) and very high (≥90% agreement).Results Responses were received from 120 healthcare professionals, including oncologists (n=73), urologists (n=16), geriatricians (n=15), nurse specialists (n=11) and hospital pharmacists (n=5). Consensus was reached for 37 out of 39 (95%) statements, and 27/39 (69%) statements achieved very high agreement ≥90%. Consensus was not reached for 2/39 (5%) statements.Conclusions Based on the consensus observed, the steering group developed a set of recommendations for the clinical utility of ADT+DOCE+ARTA in treating patients with mHSPC in the UK. Following these recommendations enables clinicians to identify appropriate patients with mHSPC for triplet treatment, thereby improving patients’ outcomes.https://bmjopen.bmj.com/content/14/11/e090013.full |
| spellingShingle | Louisa Fleure Amit Bahl Suneil Jain Vincent Khoo Noel Clarke Tania Kalsi Hilary Glen Junaid Mobeen A modified Delphi consensus regarding the clinical utility of triplet therapy in patients with metastatic hormone-sensitive prostate cancer patients in the UK BMJ Open |
| title | A modified Delphi consensus regarding the clinical utility of triplet therapy in patients with metastatic hormone-sensitive prostate cancer patients in the UK |
| title_full | A modified Delphi consensus regarding the clinical utility of triplet therapy in patients with metastatic hormone-sensitive prostate cancer patients in the UK |
| title_fullStr | A modified Delphi consensus regarding the clinical utility of triplet therapy in patients with metastatic hormone-sensitive prostate cancer patients in the UK |
| title_full_unstemmed | A modified Delphi consensus regarding the clinical utility of triplet therapy in patients with metastatic hormone-sensitive prostate cancer patients in the UK |
| title_short | A modified Delphi consensus regarding the clinical utility of triplet therapy in patients with metastatic hormone-sensitive prostate cancer patients in the UK |
| title_sort | modified delphi consensus regarding the clinical utility of triplet therapy in patients with metastatic hormone sensitive prostate cancer patients in the uk |
| url | https://bmjopen.bmj.com/content/14/11/e090013.full |
| work_keys_str_mv | AT louisafleure amodifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk AT amitbahl amodifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk AT suneiljain amodifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk AT vincentkhoo amodifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk AT noelclarke amodifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk AT taniakalsi amodifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk AT hilaryglen amodifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk AT junaidmobeen amodifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk AT louisafleure modifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk AT amitbahl modifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk AT suneiljain modifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk AT vincentkhoo modifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk AT noelclarke modifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk AT taniakalsi modifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk AT hilaryglen modifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk AT junaidmobeen modifieddelphiconsensusregardingtheclinicalutilityoftriplettherapyinpatientswithmetastatichormonesensitiveprostatecancerpatientsintheuk |